Valneva SE (VALN) Other Non Operating Income (2021 - 2026)
Valneva SE (VALN) posted quarterly Other Non Operating Income of -$3.4 million for Q1 2026, down 181.42% year-on-year from $4.2 million in Q1 2025, and down 232.0% on a QoQ basis from -$1.0 million in Q4 2025.
Valneva SE (VALN) Other Non Operating Income (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Other Non Operating Income for 6 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.
- Quarterly Other Non Operating Income fell 181.42% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.8 million (down 247.71% YoY) and the FY2025 annual result came in at -$8.2 million, down 325.0% from the prior year.
- Other Non Operating Income slipped to -$3.4 million in Q1 2026 per VALN's latest filing, from -$1.0 million in the prior quarter.
- Over the last five years, Other Non Operating Income for VALN reached as high as $15.8 million in Q4 2022 and fell as low as -$18.0 million in Q3 2022.
- A 5-year average of -$937205.8 and a median of -$1.0 million in 2025 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income jumped 397.32% — and 2025, when it slumped 944.73%.
- Year by year, Other Non Operating Income stood at $15.8 million in 2022, then sank by 49.55% to $8.0 million in 2023, then decreased by 11.62% to $7.1 million in 2024, then sank by 114.52% to -$1.0 million in 2025, then tumbled by 232.0% to -$3.4 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$3.4 million, -$1.0 million, and -$16.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -1.02 Mn |
| Sep 30, 2025 | -16.03 Mn |
| Jun 30, 2025 | 4.68 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 7.06 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | 978,640.67 |
| Mar 31, 2024 | -2.86 Mn |
| Dec 31, 2023 | 7.98 Mn |
| Sep 30, 2023 | -6.78 Mn |
| Jun 30, 2023 | 1.53 Mn |
| Mar 31, 2023 | 3.61 Mn |
| Dec 31, 2022 | 15.82 Mn |
| Sep 30, 2022 | -18.02 Mn |
| Jun 30, 2022 | -9.38 Mn |
| Mar 31, 2022 | -2.74 Mn |
| Dec 31, 2021 | 3.18 Mn |
| Sep 30, 2021 | -3.87 Mn |